



Our Core Strengths Create the Foundation for Diversified, Durable Growth and Dependable Performance.

As a global medical technology innovator leading the way in women's health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are rooted in *The Science of Sure®*, our promise to deliver world-class certainty, precision and quality to healthcare providers and their patients.

DIVISION	CORE PRODUCTS	EXPANDING PORTFOLIO	
DIAGNOSTIC SOLUTIONS	Panther System® • Aptima® STI Assays • ThinPrep® Pap Test and Cytology Instruments	Aptima BV and CV/TV Assays - Nucleic acid amplification tests. - Used to detect the three leading causes of vaginosis and vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis. Breast Cancer Index Test™ - Used to predict which breast cancer patients are likely to benefit from extended endocrine therapy. - The only test of its kind recognized by key medical societies. - Reimbursed by Medicare and key insurance providers. Panther Fusion® Assays - Expand the molecular assay menu running efficiently on Panther Scalable Solutions. - Syndromic solutions (Respiratory & GI assays) enable testing tailored to the individual, reducing unnecessary use of resources and time.	Panther Fusion® and Panther Scalable Solutions - Provides access to Hologic's full menu of molecular diagnostic tests. - Allows labs to expand existing molecular testing capabilities. - Increases flexibility, capacity and walkaway time. Genius Digital Cytology - First CE-marked digital cytology platform to combine an artificial intelligence (AI) algorithm with advanced volumetric imaging technology. - Comprehensive cervical cancer screening portfolio — from sample collection to digital diagnosis. - Helps healthcare providers by supplying critical information needed to help guide earlier detection and better treatment decisions.
BREAST & SKELETAL HEALTH SOLUTIONS	3Dimensions® • Affirm® Breast Biopsy Systems • Trident® Specimen Radiography System • Localizer™ Wire-free Guidance System	Brevera® - Breast biopsy system provides real-time imaging and analysis of specimens. - Intuitive user interface and automated specimen collection. - Streamlined, accurate procedures reduce a patient's time under breast compression. Genius AI™ - Supports radiologists in improving accuracy and consistency of breast cancer detection. - Designed to maximize effectiveness of 3D mammography. - Software is fully integrated on 3Dimensions systems.	Interventional Needles - Portfolio of tissue-acquisition needles that function with stereotactic and ultrasound systems. - Provide ease of use with world-class accuracy, consistency and efficiency. Tissue Markers - Serve a fast-expanding market of products for breast-conserving surgery. - Minimally invasive innovations that enable imaging and radiation treatment. - Completed Endomagetics acquisition in July 2024, adding additional localization and tracing products to portfolio.
GYN SURGICAL SOLUTIONS	NovaSure® • MyoSure®	Fluent® Pro - Fluid management system for hysteroscopies. - Provides simplified set-up and operation. - Advanced technology designed to increase clinical confidence. Sonata System - Transcervical fibroid ablation for treatment of symptomatic uterine fibroids. - Delivers a breakthrough alternative to hysterectomy and myomectomy. - Incisionless, transcervical delivery avoids the peritoneal cavity, allowing faster recovery times.	CoolSeal® Portfolio - Gold-standard efficacy of advanced bipolar RF vessel sealing technology. - Versatile applications for pediatric and gynecologic procedures. - Devices cut and dissect with precision in tight spaces and with minimal thermal footprint. Omni® Hysteroscopes - Three interchangeable sheaths to enable flexible diagnosis and treatment with a single instrument. - Provide a clear view of the cervical canal and uterine cavity.

Growing Performance, Growing Impact and Growing Recognition

Revenue Highlights 3Q25

Revenue (\$M)	3Q25	Reported Delta vs. 3Q24	CC Delta vs. 3Q24
Diagnostics	\$448.9	1.8%	0.9%
Organic Diagnostics ex. COVID-19 ²	\$410.4	3.9%	2.9%
Organic Molecular Diag. ex. COVID-19 ²	\$289.0	6.0%	5.2%
Breast Health	\$365.2	(5.1%)	(5.8%)
Organic Breast Health ²	\$345.5	(10.1%)	(10.8%)
GYN Surgical	\$178.4	7.1%	6.3%
Organic Surgical ²	\$169.9	2.0%	1.2%
Skeletal Health	\$31.3	64.7%	62.1%
Total Revenue	\$1,023.8	1.2%	0.4%
Organic Revenue ²	\$988.6	(1.4%)	(2.3%)
Organic ex. COVID-19 ³	\$957.1	(0.8%)	(1.7%)
US Revenue	\$760.7	(0.6%)	
International Revenue	\$263.1	6.9%	3.5%

Financial Overview 3Q25

Non-GAAP in Millions ex. EPS	3Q25	Delta vs. 3Q24
Revenue (\$M)	\$1023.8	1.2%
Organic Revenue ²	\$988.6	(1.4%)
Organic ex COVID-19 ³	\$957.1	(0.8%)
Gross Margin	60.3%	(80) bps
Operating Expenses	\$309.6	2.2%
Operating Margin	30.1%	(110) bps
Net Margin	23.8%	(100) bps
Diluted EPS	\$1.08	1.9%
Adjusted EBITDA	\$340.9	0.7%

Financial Guidance for Fourth Quarter Fiscal 2025

Q4 2025	Guidance \$	Reported vs. 4Q24	CC vs. 4Q24	Organic vs. 4Q24 ²	Organic ex. COVID-19 ² vs. 4Q24
Revenue (\$M)	\$1,030 - \$1,040	4.3% to 5.3%	3.7% to 4.7%	2.7% to 3.7%	3.9% to 5.0%
GAAP EPS	\$0.90 - \$0.93	18.4% to 22.4%			
Non-GAAP EPS	\$1.09 - \$1.12	7.9% to 10.9%			

Financial Guidance for Full Year Fiscal 2025

Fiscal 2025	Guidance \$	Reported vs. FY24	CC vs. FY24	Organic vs. FY24	Organic ex. COVID-19 ² vs. FY24
Revenue (\$M)	\$4,081 - \$4,091	1.3% to 1.5%	1.1% to 1.4%	(0.5%) to (0.2%)	0.6% to 0.8%
GAAP EPS	\$2.56 - \$2.59	(22.9%) to (22.0%)			
Non-GAAP EPS	\$4.23 - \$4.26	3.7% to 4.4%			

Capital Deployment Priorities

- Expect strong cash flow in our fiscal fourth quarter and the full year 2025.
- Continuing to invest in ourselves through M&A and share repurchases.
- Business development priorities:
 - Tuck-in acquisitions
 - Attractive to revenue, EPS growth rates
 - Attractive ROIC
 - Leverage existing strengths

Financial Results


Net Debt & Leverage Ratio¹




Revenue & CC Growth Rates



Non-GAAP EPS & Growth Rates




2024 Divisional Revenue by Geography



Adjusted Operating Cash Flow⁴



ROIC



Purpose-Driven Company



Through our substantial commitment to R&D innovation, we generate strong financial results, allowing us to invest in groundbreaking health initiatives for women and underserved communities.



Global Health:

- Hologic Global Women's Health Index represents the views of 94% of the world's women and girls aged 15 or older.
- Global Access Initiative provides cost-effective, high-quality diagnostic testing across sub-Saharan Africa.
- Philanthropic donations aid charitable groups focused on women's health, STEM education and social equality.



Global Reach:

Locations in 36+ countries with direct staff and a market presence in more than 100 countries.



Global Headquarters:

Marlborough, Massachusetts, USA.

¹ Net debt is total debt minus cash; leverage ratio. ² Organic revenue excludes Endomagetrics, Gynesonics, and the divested Blood and SSI businesses. ³ Total organic revenue excluding COVID-19. ⁴ Operating cash flow adjusted for one-time tax and litigation items.
© 2024 Hologic Inc. All rights reserved. Hologic and The Science of Sure are trademarks of Hologic Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions, Access, Affirm, Aptima, Breast Cancer Index, Brevera, CoolSeal, Dimensions, Fluent, Localizer, MyoSure, NovaSure, Novodiag, Panther, Panther Fusion, ThinPrep. All other trademarks, registered trademarks and product names are the property of their respective owners.